LOSCOCCO, GIUSEPPE GAETANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.350
AS - Asia 2.847
EU - Europa 2.511
SA - Sud America 407
AF - Africa 82
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.236
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.244
RU - Federazione Russa 918
CN - Cina 849
SG - Singapore 784
IT - Italia 723
HK - Hong Kong 321
BR - Brasile 320
KR - Corea 270
VN - Vietnam 220
FI - Finlandia 123
IE - Irlanda 122
BD - Bangladesh 119
FR - Francia 101
GB - Regno Unito 101
DE - Germania 95
SE - Svezia 88
NL - Olanda 76
CA - Canada 69
IN - India 69
CH - Svizzera 61
ID - Indonesia 44
AU - Australia 38
JP - Giappone 35
JO - Giordania 34
AR - Argentina 32
ES - Italia 31
MX - Messico 25
EC - Ecuador 18
TW - Taiwan 17
CZ - Repubblica Ceca 16
TR - Turchia 15
NG - Nigeria 14
ZA - Sudafrica 14
AT - Austria 11
CI - Costa d'Avorio 10
IQ - Iraq 10
CO - Colombia 9
GR - Grecia 9
MY - Malesia 9
UA - Ucraina 9
CL - Cile 8
MA - Marocco 8
PK - Pakistan 8
PL - Polonia 8
BJ - Benin 7
EG - Egitto 6
KE - Kenya 6
PY - Paraguay 6
UZ - Uzbekistan 6
VE - Venezuela 6
DZ - Algeria 5
JM - Giamaica 5
KZ - Kazakistan 5
SA - Arabia Saudita 5
PE - Perù 4
PH - Filippine 4
SI - Slovenia 4
UY - Uruguay 4
AL - Albania 3
DO - Repubblica Dominicana 3
IL - Israele 3
NP - Nepal 3
OM - Oman 3
AE - Emirati Arabi Uniti 2
DK - Danimarca 2
HU - Ungheria 2
LT - Lituania 2
LU - Lussemburgo 2
LV - Lettonia 2
PS - Palestinian Territory 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AZ - Azerbaigian 1
BB - Barbados 1
BT - Bhutan 1
BW - Botswana 1
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
HR - Croazia 1
KW - Kuwait 1
LB - Libano 1
MM - Myanmar 1
MU - Mauritius 1
RO - Romania 1
RW - Ruanda 1
TH - Thailandia 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
Totale 9.236
Salva come PNG Salva come JPEG
Città #
Santa Clara 975
Singapore 574
Ashburn 445
Hefei 307
Hong Kong 283
Seoul 269
San Jose 162
Dublin 122
Fairfield 101
Milan 98
Chandler 96
Beijing 94
Los Angeles 89
Ho Chi Minh City 80
Council Bluffs 76
Helsinki 74
Florence 66
New York 66
Moscow 64
Lauterbourg 62
Buffalo 60
Bern 59
Houston 57
Hanoi 44
Munich 43
Altamura 42
Kent 42
Rome 42
Woodbridge 42
Lawrence 41
Seattle 39
London 33
Melbourne 33
Boston 31
Cambridge 31
Dallas 31
Jakarta 30
The Dalles 30
São Paulo 28
Shanghai 26
Turku 26
Wilmington 26
Princeton 25
Mumbai 23
Paris 22
Lappeenranta 21
Tokyo 20
Bologna 18
Toronto 18
Boardman 17
Frankfurt am Main 15
Prague 15
Barcelona 14
Bengaluru 14
Naples 14
Taipei 14
Amsterdam 13
Abuja 12
Chicago 12
Ealing 12
Montreal 12
Ann Arbor 11
Manchester 11
Abidjan 10
Brooklyn 10
Chennai 10
Fiesole 10
Modena 10
Orem 10
Rio de Janeiro 10
The Hague 10
Turin 10
City of London 9
Guayaquil 9
Johannesburg 9
Miano 9
San Diego 9
Atlanta 8
Bremen 8
Catania 8
Da Nang 8
Falkenstein 8
Genoa 8
Haiphong 8
Hamilton 8
Mexico City 8
Philadelphia 8
Tianjin 8
Vancouver 8
Vienna 8
Waltham 8
Amman 7
Ankara 7
Biên Hòa 7
Campinas 7
Cotonou 7
Curitiba 7
Düsseldorf 7
Hải Dương 7
Phoenix 7
Totale 5.582
Salva come PNG Salva come JPEG
Nome #
Essential Thrombocythemia 335
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 266
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 200
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 195
Kaposi Sarcoma in a patient treated with Ruxolitinib 194
A case of disseminated Blastic Plasmocytoid Dendritic Cell Neoplasm 192
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 191
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 190
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 187
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 185
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 182
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 180
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 179
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 178
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 178
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 178
CALR mutation burden in essential thrombocythemia and disease outcome 174
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience 170
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 162
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 160
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 158
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 158
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 157
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 156
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 155
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 154
Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm 153
Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies 149
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 149
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 148
Mutations and thrombosis in essential thrombocythemia 143
Impact of mutational profile on the management of myeloproliferative neoplasms: A short review of the emerging data 142
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 138
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 138
Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis 135
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 135
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 134
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases 134
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 134
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 133
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 127
Myeloid sarcoma: more and less than a distinct entity 125
The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19 125
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia 122
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives 119
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 119
T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker 118
Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease 117
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis 111
Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses 110
Visceral Leishmaniasis 108
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial 105
Bone marrow involvement in small cell lung cancer 105
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 100
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19 97
When and how to transplant in myelofibrosis – recent trends 96
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives 95
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis (RCO) Score in Primary Myelofibrosis 95
Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates 86
Imatinib is effective in some PDGFRA/B‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms 78
Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management 76
PCM1::JAK2 myeloproliferative neoplasm suggested by bone marrow histopathological features 76
Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy 69
Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms 64
TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance 39
Essential Thrombocythemia 13
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera 13
Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators. Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 11
Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency 10
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images 10
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm 9
Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers 7
Triple A Plus (AAA +) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients 7
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance 7
Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities 4
null 2
null 1
Totale 9.355
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.501
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.501
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022143 1 0 1 2 3 3 0 40 15 3 30 45
2022/2023626 51 117 40 29 28 88 68 30 56 12 15 92
2023/2024501 28 35 58 24 56 68 22 93 9 47 36 25
2024/20253.020 85 236 156 403 805 458 115 142 119 101 172 228
2025/20264.652 479 627 624 509 382 129 402 210 273 302 293 422
2026/2027103 103 0 0 0 0 0 0 0 0 0 0 0
Totale 9.355